openPR Logo
Press release

Lawsuit filed for Investors in shares of Humanigen, Inc. (NASDAQ: HGEN) over alleged Violations of Securities Laws

09-08-2022 03:22 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Humanigen, Inc. (NASDAQ: HGEN) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Humanigen, Inc. (NASDAQ: HGEN) shares over alleged securities laws violations.

An investor, who purchased shares of Humanigen, Inc. (NASDAQ: HGEN), filed a lawsuit over alleged violations of Federal Securities Laws by Humanigen, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN) have certain options and for certain investors are short and strict deadlines running. Deadline: October 25, 2022. NASDAQ: HGEN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Burlingame, CA based Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States.

On September 9, 2021, Humanigen, Inc. announced that "the U.S. FDA has declined its request for emergency use authorization of lenzilumab to treat newly hospitalized COVID-19 patients." Humanigen advised investors that "[i]n its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19."
Shares of Humanigen, Inc. (NASDAQ: HGEN) declined from $17.18 per share on September 2, 2021, to $6.00 per share on September 28, 2021.

Then, on July 13, 2022, Humanigen disclosed that lenzilumab had failed to show statistical significance on the primary endpoint of the ACTIV-5/BET-B study.
Shares of Humanigen, Inc. (NASDAQ: HGEN) declined to as low as $0.20 per share on September 6, 2022.

The plaintiff claims that between May 28, 2021 and July 12, 2022, the Defendants made false and/or misleading statements and/or failed to disclose that lenzilumab was less effective in treating hospitalized COVID-19 patients than Defendants had represented, that as a result, the FDA was unlikely to approve the lenzilumab EUA and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint, that accordingly, lenzilumab's clinical and commercial prospects were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Humanigen, Inc. (NASDAQ: HGEN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Humanigen, Inc. (NASDAQ: HGEN) over alleged Violations of Securities Laws here

News-ID: 2727694 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NA …
An investigation was announced for investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) shares over potential securities laws violations by Lifecore Biomedical, Inc. Investors who purchased shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Lifecore Biomedical, Inc. regarding its business, its prospects and
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over potential Wrongdoing by certain directors
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Designer Brands Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Columbus,
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. …
An investor, who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ), filed a lawsuit over alleged violations of Federal Securities Laws by Innoviz Technologies Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) have certain options and for certain investors are short and strict deadlines running. Deadline: May 14, 2024. NASDAQ: INVZ investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NASDAQ: IRBT)
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: May 7, 2024. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Humanigen

Investigation announced for Investors in Humanigen, Inc. (NASDAQ: HGEN) over pos …
An investigation was announced for Humanigen, Inc. (NASDAQ: HGEN) shares over potential securities laws violations by Humanigen, Inc. in connection with certain financial statements. Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Humanigen, Inc. regarding its business, its prospects and
Investigation announced for Investors in Humanigen, Inc. (NASDAQ: HGEN) over pot …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Humanigen, Inc. Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Humanigen, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Burlingame, CA based Humanigen,
Investigation announced for Investors in shares of Humanigen, Inc. (NASDAQ: HGEN …
An investigation was announced concerning potential securities laws violations by Humanigen, Inc. in connection with certain financial statements. Investors who purchased shares of Humanigen, Inc. (NASDAQ: HGEN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) concerning whether a series of statements
Gout Therapeutic Market with Leading Players like Boehringer Ingelheim Internati …
An off-the-shelf report on Gout Therapeutic Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as type/components/ application/industry verticals/ end-users are analyzed with robust research methodology which includes three step process starting with extensive secondary research to gather data from company profiles, global/regional associations, trade journals,
Gout Therapeutic Market Analysis to 2027 - Boehringer Ingelheim International, G …
The Gout Therapeutic market is anticipated to grow in the forecast, owing to the factors such as growing drug pipeline, easy availability, changing lifestyle, increasing alcohol consumption, high purine diet, rising obesity and kidney diseases, consumption of medicines such as diuretics, rise in demand for biologics for treatment of gout across the globe and novel launches of drugs. Low levels of physician and low patient awareness are expected to restrict
Recent Research on Chagas Disease Drug Market 2019 Industry Analysis and Regiona …
The Global Chagas Disease Drug Market forecast period from 2019 to 2026 and Increasing approval to chagas disease treatment drugs is expected propel the market growth in the forecast period. However lack of awareness about the specific treatment may hamper the market growth. Get Sample copy @ https://www.orianresearch.com/request-sample/1066131 Key Market Players: - Bayer AG, F. Hoffmann-La Roche Ltd., Humanigen Inc., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Savant Neglected Diseases, LLC,